Abstract 556P
Background
Iruplinalkib (WX-0593) is a novel ALK TKI. Here, we report the results from the phase 1 study on efficacy and safety of iruplinalkib for ALK-positive NSCLC patients who received prior second-generation ALK TKIs.
Methods
ALK- or ROS1-positive advanced NSCLC patients were enrolled in the phase 1 study. In the dose-escalation phase, patients received iruplinalkib 30–300 mg orally once daily. In the dose-expansion phase, patients received iruplinalkib 120 or 180 mg orally once daily with or without a 7-day lead-in at 60 mg. Efficacy and safety were assessed by investigators. ALK-positive patients previously treated with second-generation ALK TKIs were included in this analysis.
Results
Totally, 153 patients were enrolled in the phase 1 study, among which 11 patients (five [45%] in the dose-escalation phase and six [55%] in the dose-expansion phase) who received prior second-generation ALK TKIs were eligible for this analysis. Median age was 52 years old. Six (55%) were male. There were one (9%), four (36%), four (36%) and two (18%) patients in 90 mg, 120 mg, 180 mg, and 240 mg orally once daily group of iruplinalkib, respectively. Brain metastasis and prior treatment were summarized in the table. As of the data cut-off date on July 31, 2023, median follow-up was 53.3 months. Six patients (55%, 95% confidence interval [CI] 23%–84%) had objective response. Median progression-free survival (PFS) was 8.1 months (95% CI 2.2–30.2). Nine (82%) and three (27%) patients experienced any grade and grade ≥ 3 treatment-related adverse event (TRAE), respectively. Other endpoints were shown in the table. Table: 556P
Parameters | Results (n=11) |
Baseline brain metastasis | 7 (64%) |
Prior ALK TKIs | |
Crizotinib + second-generation | 9 (82%) |
Second-generation only | 2 (18%) |
Detailed second-generation ALK TKI | |
Ensartinib | 5 (45%) |
Conteltinib | 4 (36%) |
Ceritinib | 1 (9%) |
Brigatinib | 1 (9%) |
Prior chemotherapy | 9 (82%) |
Best objective response | |
Partial response | 6 (55%) |
Stable disease | 4 (36%) |
Progressive disease | 1 (9%) |
Objective response | 6 (55%, 95% CI 23%–83%) |
Disease control | 10 (91%, 95% CI 59%–100%) |
PFS event | 9 (82%) |
Median PFS, months | 8.1 (95% CI 2.2–30.2) |
Any grade TRAE | 9 (82%) |
Grade ≥ 3 TRAE | 3 (27%) |
TRAE leading to dose interruption/reduction/discontinuation | 2 (18%)/0/0 |
Conclusions
Iruplinalkib demonstrated promising efficacy and acceptable toxicity in ALK-positive advanced NSCLC patients previously treated with second-generation ALK TKIs.
Clinical trial identification
NCT03389815.
Editorial acknowledgement
We thank Yunjie Yu (Qilu Pharmaceutical Co., Ltd., Jinan, China) for providing medical writing support.
Legal entity responsible for the study
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs.
Funding
Qilu Pharmaceutical Co., Ltd. (Jinan, China) and China National Major Project for New Drug Innovation (2017ZX09304015).
Disclosure
M. Wang, M. Si, Y. Sang, X. Kang: Financial Interests, Personal, Full or part-time Employment: Qilu Pharmaceutical Co., Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
414P - Landscape of ERBB2 mutations in advanced cancers (AC) using circulating tumor DNA (ctDNA) next-generation sequencing (NGS) in Asia and Middle East (AME)
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract
415P - Initial experience in a real-world Asian cohort with a circulating tumor DNA (ctDNA) mutation-based multi-cancer early detection (MCED) assay
Presenter: Steven Tucker
Session: Poster Display
Resources:
Abstract
416P - Three-dimensional bioprinting model of ovarian cancer for identification of patient-specific therapy response
Presenter: Jiangang Zhang
Session: Poster Display
Resources:
Abstract
417P - Early experience in using plasma-only multi-omic minimal residual disease testing in early-stage colorectal cancer patients from Asia and the Middle East
Presenter: Shaheenah Dawood
Session: Poster Display
Resources:
Abstract
418P - Decoding the intricate cellular makeup of immune-related adverse events using single-cell and spatial analysis
Presenter: Dmitrii Shek
Session: Poster Display
Resources:
Abstract
420P - Combinatory genomic and transcriptomic sequencing of Chinese KRAS mutant non-small cell lung cancer revealed molecular and inflammatory heterogeneity in tumor microenvironment
Presenter: Xuchao Zhang
Session: Poster Display
Resources:
Abstract
421P - Comprehensive genomic profiling (CGP) unravels somatic BRCA (sBRCA) and homologous recombinant repair (HRR) gene alterations across multi-cancer spectrum
Presenter: Ramya Kodandapani
Session: Poster Display
Resources:
Abstract
422P - CD8Teff distinguished tumor immunotyping heterogeneity and enables precision immunotherapy
Presenter: luhui Mao
Session: Poster Display
Resources:
Abstract
423P - Insights into clinically actionable biomarkers in an Indian cancer cohort of 1000 patients using comprehensive genomic profiling (CGP)
Presenter: Mithua Ghosh
Session: Poster Display
Resources:
Abstract
424P - MD Anderson Cancer Center global precision oncology decision support (Glo-PODS) clinical trial genomic support: Pilot program at the Prince of Wales Hospital (Chinese University of Hong Kong - CUHK)
Presenter: Brigette Ma
Session: Poster Display
Resources:
Abstract